Li Sun

Li Sun is the founder and CEO of Shennon Biotechnologies, a San Francisco single-cell immunotherapy company that profiles millions of immune cells in hours to pinpoint the rare T cells and antibody targets that fight cancer. A physicist by training (PhD from Harvard's Weitz lab, M.Eng from MIT), she spent five years as a deep-tech venture investor at Bessemer and Foundation Capital before building the platform herself. Shennon emerged from stealth in March 2023 with a $13M seed round led by DCVC.